Experts are sounding the alarm after a report that popular weight-loss injectable manufacturer Novo Nordisk spent $11 million last year on meals and travel for thousands of prescribing doctors.
The company purchased more than 457,000 meals—at a total price of more than $9 million—to educate prescribers about Wegovy and other similar drugs it sells, known as GLP-1 agonists, according to a July 5 STAT report.
